Compare AJANTA PHARMA with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs DISHMAN PHARMA - Comparison Results

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA DISHMAN PHARMA AJANTA PHARMA/
DISHMAN PHARMA
 
P/E (TTM) x 25.4 25.1 101.2% View Chart
P/BV x 7.1 3.3 210.7% View Chart
Dividend Yield % 0.5 0.7 75.2%  

Financials

 AJANTA PHARMA   DISHMAN PHARMA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-19
DISHMAN PHARMA
Mar-16
AJANTA PHARMA/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,422374 379.8%   
Low Rs898129 696.4%   
Sales per share (Unadj.) Rs233.5197.8 118.1%  
Earnings per share (Unadj.) Rs44.021.2 207.3%  
Cash flow per share (Unadj.) Rs52.234.7 150.2%  
Dividends per share (Unadj.) Rs9.002.00 450.0%  
Dividend yield (eoy) %0.80.8 97.6%  
Book value per share (Unadj.) Rs255.1179.9 141.8%  
Shares outstanding (eoy) m88.0280.69 109.1%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x5.01.3 390.4%   
Avg P/E ratio x26.411.9 222.3%  
P/CF ratio (eoy) x22.27.2 306.8%  
Price / Book Value ratio x4.51.4 325.0%  
Dividend payout %20.59.4 217.1%   
Avg Mkt Cap Rs m102,08120,306 502.7%   
No. of employees `0006.80.8 820.3%   
Total wages/salary Rs m4,3075,355 80.4%   
Avg. sales/employee Rs Th3,022.619,252.7 15.7%   
Avg. wages/employee Rs Th633.46,459.5 9.8%   
Avg. net profit/employee Rs Th569.12,064.1 27.6%   
INCOME DATA
Net Sales Rs m20,55415,961 128.8%  
Other income Rs m211265 79.4%   
Total revenues Rs m20,76516,226 128.0%   
Gross profit Rs m5,6644,103 138.0%  
Depreciation Rs m7211,091 66.1%   
Interest Rs m12944 1.2%   
Profit before tax Rs m5,1432,334 220.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,273624 204.1%   
Profit after tax Rs m3,8701,711 226.2%  
Gross profit margin %27.625.7 107.2%  
Effective tax rate %24.826.7 92.6%   
Net profit margin %18.810.7 175.6%  
BALANCE SHEET DATA
Current assets Rs m11,81211,018 107.2%   
Current liabilities Rs m3,7769,517 39.7%   
Net working cap to sales %39.19.4 415.8%  
Current ratio x3.11.2 270.2%  
Inventory Days Days77110 70.0%  
Debtors Days Days8235 234.2%  
Net fixed assets Rs m14,39816,304 88.3%   
Share capital Rs m175161 108.7%   
"Free" reserves Rs m22,27712,907 172.6%   
Net worth Rs m22,45214,516 154.7%   
Long term debt Rs m74,189 0.2%   
Total assets Rs m26,96229,805 90.5%  
Interest coverage x444.33.5 12,801.4%   
Debt to equity ratio x00.3 0.1%  
Sales to assets ratio x0.80.5 142.4%   
Return on assets %14.48.9 161.6%  
Return on equity %17.211.8 146.2%  
Return on capital %23.017.5 130.9%  
Exports to sales %024.8 0.0%   
Imports to sales %03.7 0.0%   
Exports (fob) Rs mNA3,956 0.0%   
Imports (cif) Rs mNA596 0.0%   
Fx inflow Rs m10,6824,952 215.7%   
Fx outflow Rs m2,102697 301.7%   
Net fx Rs m8,5804,255 201.7%   
CASH FLOW
From Operations Rs m3,7482,786 134.5%  
From Investments Rs m-2,228-1,529 145.7%  
From Financial Activity Rs m-1,475-941 156.7%  
Net Cashflow Rs m45316 14.3%  

Share Holding

Indian Promoters % 73.8 61.4 120.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 3.7 41.9%  
FIIs % 7.6 12.7 59.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 22.1 76.9%  
Shareholders   20,968 46,261 45.3%  
Pledged promoter(s) holding % 4.4 35.8 12.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   SUN PHARMA  PROCTER & GAMBLE HEALTH  NOVARTIS  UNICHEM LAB  ORCHID PHARMA  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 244 Points Lower, Nifty Ends Below 14,300; UltraTech Cement & HCL Tech Top Losers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended lower.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 64.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 64.2% YoY). Sales on the other hand came in at Rs 7 bn (up 15.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 28.9% (Quarterly Result Update)

Aug 24, 2020 | Updated on Aug 24, 2020

For the quarter ended June 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 7 bn (up 9.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 45.3% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 45.3% YoY). Sales on the other hand came in at Rs 7 bn (up 32.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 60.8% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 60.8% YoY). Sales on the other hand came in at Rs 7 bn (up 34.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

11x Bankruptcy to Bluechip Stock: A Rare India Revival Story(Profit Hunter)

Apr 16, 2021

There is no stopping this 11-bagger stock from significant upside.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Warning About Bubbles(Fast Profits Daily)

Apr 16, 2021

Those who don't learn from financial history are doomed to lose their money.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Apr 20, 2021 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS